Taken together, these metabolic findings could suggest greater risk of glucose dysmetabolism and eventual T2D in SAM survivors, albeit in the current absence of overtly impaired insulin sensitivity or clinical disease that may develop with obesity and age based on oral glucose tolerance test (OGTT) (35). This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.